

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM439756

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
RESUBMIT DOCUMENT ID:	700520351		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Valeant Pharmaceuticals International, Inc. (successor in interest to King George Holdings Luxembourg IIA S.a.r.l.)		07/12/2017	Corporation: CANADA
RECEIVING PARTY DATA			
Name:	Acorda Therapeutics, Inc.,		
Street Address:	420 Saw Mill River Road		
City:	Ardsley		
State/Country:	NEW YORK		
Postal Code:	10502		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	1906277	ZANAFLEX	
Registration Number:	2383531	ZANAFLEX	
Registration Number:	3341341	ZANAFLEX CAPSULES	
CORRESPONDENCE DATA			
Fax Number:			
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	585-231-1197		
Email:	kmarkert@hselaw.com, trademarks@hselaw.com		
Correspondent Name:	Katherine A. Markert		
Address Line 1:	1600 Bausch & Lomb Place		
Address Line 2:	Harter Secrest & Emery LLP		
Address Line 4:	ROCHESTER, UNITED STATES 14604		
NAME OF SUBMITTER:	Katherine A. Markert		
SIGNATURE:	/Katherine A. Markert/		
DATE SIGNED:	08/18/2017		

CH \$90.00 1906277

Total Attachments: 11

source=Release of Trademark Security Interest (Acorda)#page1.tif

source=Release of Trademark Security Interest (Acorda)#page2.tif

source=Release of Trademark Security Interest (Acorda)#page3.tif

source=Release of Trademark Security Interest (Acorda)#page4.tif

source=Release of Security Interest with USPTO Notice#page1.tif

source=Release of Security Interest with USPTO Notice#page2.tif

source=Release of Security Interest with USPTO Notice#page3.tif

source=Release of Security Interest with USPTO Notice#page4.tif

source=Release of Security Interest with USPTO Notice#page5.tif

source=Release of Security Interest with USPTO Notice#page6.tif

source=Release of Security Interest with USPTO Notice#page7.tif

RELEASE OF TRADEMARK SECURITY INTEREST

This **RELEASE OF TRADEMARK SECURITY INTEREST** (this "Release") is executed as of July 12, 2017 by Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia, Canada (the "Releasor") in favor of Acorda Therapeutics, Inc., a Delaware corporation (the "Releasee").

WITNESSETH:

WHEREAS, Releasee and King George Holdings Luxembourg IIA S.a.r.l., a Luxembourg private limited company ("King George") entered into that certain Revenue Interests Assignment Agreement, dated December 23, 2005 (the "RIAA"), pursuant to which Releasee assigned certain interests to King George (the "Royalty Interests");

WHEREAS, in connection with the RIAA, Releasee and King George entered into, inter alia, that certain Security Agreement, dated December 23, 2005 (the "Security Agreement"), pursuant to which Releasee granted King George a security interest in certain Collateral (as such term is defined in the Security Agreement), including but not limited to the trademarks referred to in Schedule A and all goodwill associated therewith (the "Trademark Collateral");

WHEREAS, in connection with the Security Agreement, such UCC Financing Statement was recorded with the United States Patent and Trademark Office on January 27, 2006, at Reel/Frame 3235/0688;

WHEREAS, King George and Releasor entered into that certain Purchase and Sale Agreement, dated October 15, 2014 (the "Purchase Agreement"), pursuant to which King George agreed to sell, assign, transfer and convey to Releasor, and Releasor agreed to purchase, acquire and accept from King George, all of King George's right, title and interest in and to the Royalty Interests and the Security Agreement;

WHEREAS, in connection with the Purchase Agreement, the parties entered into that certain Assignment of Security Interest, dated October 17, 2014 (the "Assignment") to assign to Releasor King George's security interest in the Trademark Collateral; and

WHEREAS, the Releasee has requested and Releasor has agreed to provide this Release to terminate and release its security interest in the Trademark Collateral.

NOW, THEREFORE, the Releasor hereby agrees as follows:

Section 1. Defined Terms. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement.

Section 2. Release of Security Interest. Releasor hereby terminates and releases any and all security interests it may have in the Trademark Collateral without warranty or recourse of any kind (express or implied). Releasor hereby authorizes Releasee or Releasee's agents or designees to record this Release with the United States Patent and Trademark Office and any foreign intellectual property registrars.


Section 3. Governing Law. THIS RELEASE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Assignor has caused this RELEASE OF TRADEMARK SECURITY INTEREST to be executed as of the date first set forth above.

RELEASOR:

VALEANT PHARMACEUTICALS
INTERNATIONAL, INC.

By: 
Name: Alex Matheson
Title: VP, Asst. General Counsel

[Signature Page to Release of Trademark Security Interest]

TRADEMARK
REEL: 006135 FRAME: 0205

EXHIBIT A

<u>Title</u>	<u>Country</u>	<u>Serial No.</u>	<u>Reg. (Pub.) No.</u>	<u>Reg. (Pub.) Date</u>
ZANAFLEX	US	74/400,930	1906277	07/18/1995
ZANAFLEX	US	75/186,534	2383531	09/05/2000
ZANAFLEX CAPSULES	US	78/713,378	3341341	11/20/2007

EXHIBIT A

<u>Title</u>	<u>Country</u>	<u>Serial No.</u>	<u>Reg. (Pub.) No.</u>	<u>Reg. (Pub.) Date</u>
ZANAFLEX	US	74/400,930	1906277	07/18/1995
ZANAFLEX	US	75/186,534	2383531	09/05/2000
ZANAFLEX CAPSULES	US	78/713,378	3341341	11/20/2007